Strategic Pharma Partnerships Immunai has active collaborations with Bristol Myers Squibb, Teva and Parker Institute, signaling strong pharma credibility and a clear path to enterprise collaborations for AI powered immune profiling and therapeutic discovery using the AMICA knowledgebase.

AI Platform Advantage The IDE engine built on AMICA enables an AI driven immune profiling platform offering sponsors accelerated target discovery, biomarker development, and patient stratification through licensed access or joint development arrangements.

Leadership & Funding Strong leadership and funding position Immunai to scale partnerships with big pharma and academia, anchored by board member Mikael Dolsten from Pfizer and 215 million dollars in funding.

Immune Profiling Leader Industry leadership in single cell immune profiling reinforced by the Immunai Grand Collaboration Initiative and AMICA expansions aligns with market demand for annotated multi omics data and AI driven drug discovery.

Scalable Operations Cloud native and data infrastructure orientation including AWS CloudFormation enables scalable integration with client workflows and compliant analytics for regulated life sciences programs.